The hepatocellular carcinoma therapy market is gradually evolving and experiencing substantial growth. While angiogenesis inhibitors, including sorafenib (Bayer / Amgen), Stivarga (Bayer), Lenvima (Eisai / Merck & Co.), Cabometyx (Exelixis / Ipsen / Takeda), and Cyramza (Eli Lilly), have been central to the treatment of advanced disease, the market is expected to undergo a significant shift over the next 10 years. This shift will be driven by the approvals of Tecentriq (Roche / Genentech) plus bevacizumab and of Imfinzi plus Imjudo (AstraZeneca / MedImmune); the FDA’s accelerated approval of Opdivo plus Yervoy (Bristol Myers Squibb / Ono Pharmaceutical); and the anticipated entry of novel immune checkpoint inhibitor-based combinations. The expected uptake of these premium-priced regimens and their label expansion to the untapped early-stage setting will drive robust growth of the hepatocellular carcinoma therapy market, in which unmet needs remain to offer further opportunities for growth.
Questions answered
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.